Pharmacodynamic Effects of Low-dose Rivaroxaban in Combination With Antiplatelet Therapies in Patients With Coronary and Peripheral Artery Disease Manifestations
Phase of Trial: Phase IV
Latest Information Update: 13 Feb 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Ticagrelor
- Indications Coronary artery disease; Peripheral arterial disorders
- Focus Pharmacodynamics
- 05 Feb 2019 Status changed from not yet recruiting to recruiting.
- 27 Dec 2018 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
- 01 Nov 2018 New trial record